UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 364

Sortiert nach

Genomics of lethal prostate cancer at diagnosis and castration resistance

The Journal of clinical investigation, 2020-04, Vol.130 (4), p.1743-1751

2020

Volltextzugriff (PDF)

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial

The lancet oncology, 2014-08, Vol.15 (9), p.975-985

2014

Volltextzugriff (PDF)

Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study

BMC cancer, 2019-01, Vol.19 (1), p.60-60, Article 60

2019

Volltextzugriff (PDF)

Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.5007-5007

2019

Volltextzugriff (PDF)

Initial active surveillance for patients with metastatic renal cell carcinoma: 10 years' experience at a regional cancer Centre

Cancer medicine (Malden, MA), 2023-03, Vol.12 (5), p.5255-5264

2023

Volltextzugriff (PDF)

A phase II trial of cabazitaxel as second line chemotherapy in relapsed locally advanced and/or metastatic carcinoma of the penis

Journal of international medical research, 2019-10, Vol.47 (10), p.4664-4672

2019

Volltextzugriff (PDF)

Assessing the Effect of a Contouring Protocol on Postprostatectomy Radiotherapy Clinical Target Volumes and Interphysician Variation

International journal of radiation oncology, biology, physics, 2009-11, Vol.75 (4), p.990-993

2009

Volltextzugriff (PDF)

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

The New England journal of medicine, 2015-10, Vol.373 (18), p.1697-1708

2015

Volltextzugriff (PDF)

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

The lancet oncology, 2020-01, Vol.21 (1), p.162-174

2020

Volltextzugriff (PDF)

Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe

European urology, 2018-07, Vol.74 (1), p.37-45

2018

Volltextzugriff (PDF)

Ten-Year Outcomes of Moderately Hypofractionated Salvage Postprostatectomy Radiation Therapy and External Validation of a Contemporary Multivariable Nomogram for Biochemical Failure

International journal of radiation oncology, biology, physics, 2020-06, Vol.107 (2), p.288-296

2020

Volltextzugriff (PDF)

Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer

Journal of clinical oncology, 2017-01, Vol.35 (1), p.48-55

2017

Volltextzugriff (PDF)

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

The Lancet (British edition), 2016-03, Vol.387 (10024), p.1163-1177

2016

Volltextzugriff (PDF)

Integrins and extracellular matrix: a novel mechanism of multidrug resistance

Expert review of anticancer therapy, 2002-08, Vol.2 (4), p.449-459

2002

Volltextzugriff (PDF)

Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)

Journal of clinical oncology, 2021-01, Vol.39 (3), p.190-201

2021

Volltextzugriff (PDF)

Predictive value of C reactive protein (CRP) in patients with metastatic renal cell carcinoma (mRCC) treated with pembrolizumab (pembro) and axitinib (axi)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.716-716

2023

Volltextzugriff (PDF)

Tolerability of Concurrent Chemoradiation Therapy With Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy, in Muscle Invasive Bladder Cancer

International journal of radiation oncology, biology, physics, 2017-03, Vol.97 (4), p.732-739

2017

Volltextzugriff (PDF)

A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients

Radiotherapy and oncology, 2016-11, Vol.121 (2), p.299-303

2016

Volltextzugriff (PDF)

Real-world survival outcomes of patients (pts) treated with 6-weekly pembrolizumab 400mg (pem6w) plus axitinib (axi) for advanced renal cell carcinoma (aRCC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.645-645

2023

Volltextzugriff (PDF)

P22. The Bladder Cancer Pathway: An analysis of the time taken to treat in a local centre

European journal of surgical oncology, 2015-11, Vol.41 (11), p.S275-S275

2015

Volltextzugriff (PDF)

PD56-07 OUTCOMES OF PENILE CANCER PATIENTS WITH MICRO-METASTASES IN DYNAMIC SENTINEL LYMPH NODE BIOPSY SPECIMENS. AN EUROGEN COLLABORATION

The Journal of urology, 2019-04, Vol.201 (Supplement 4)

2019

Volltextzugriff (PDF)

VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis

British journal of cancer, 2022-01, Vol.126 (1), p.34-41

2022

Volltextzugriff (PDF)

A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first‐line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin

BJU international, 2020-08, Vol.126 (2), p.292-299

2020

Volltextzugriff (PDF)

1 – 25 von 364

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(321)
Mit Volltextzugriff
(330)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(363)
Japanisch
(34)

Erscheinungsjahr

n.n

Thema

Science & Technology
(223)
Life Sciences & Biomedicine
(201)
Humans
(130)
Male
(95)
Female
(65)
Middle Aged
(61)
Biological And Medical Sciences
(56)
Animals
(53)
Aged
(51)
Environmental Sciences
(36)
Environmental Sciences & Ecology
(36)
Medical Sciences
(36)
Adult
(35)
Treatment Outcome
(32)
General & Internal Medicine
(29)
Toxicology
(28)
Fundamental And Applied Biological Sciences. Psychology
(27)
Oncology
(27)
Birds
(26)
Medicine, General & Internal
(26)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Genomics of lethal prostate cancer at diagnosis and castration resistance

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial

Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study

Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis

Initial active surveillance for patients with metastatic renal cell carcinoma: 10 years' experience at a regional cancer Centre

A phase II trial of cabazitaxel as second line chemotherapy in relapsed locally advanced and/or metastatic carcinoma of the penis

Assessing the Effect of a Contouring Protocol on Postprostatectomy Radiotherapy Clinical Target Volumes and Interphysician Variation

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe

Ten-Year Outcomes of Moderately Hypofractionated Salvage Postprostatectomy Radiation Therapy and External Validation of a Contemporary Multivariable Nomogram for Biochemical Failure

Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Integrins and extracellular matrix: a novel mechanism of multidrug resistance

Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)

Predictive value of C reactive protein (CRP) in patients with metastatic renal cell carcinoma (mRCC) treated with pembrolizumab (pembro) and axitinib (axi)

Tolerability of Concurrent Chemoradiation Therapy With Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy, in Muscle Invasive Bladder Cancer

A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients

Real-world survival outcomes of patients (pts) treated with 6-weekly pembrolizumab 400mg (pem6w) plus axitinib (axi) for advanced renal cell carcinoma (aRCC)

P22. The Bladder Cancer Pathway: An analysis of the time taken to treat in a local centre

PD56-07 OUTCOMES OF PENILE CANCER PATIENTS WITH MICRO-METASTASES IN DYNAMIC SENTINEL LYMPH NODE BIOPSY SPECIMENS. AN EUROGEN COLLABORATION

VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis

A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first‐line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial

Suchergebnisse filtern